Table 2. Hepatic, Renal, and Skin Toxicity (Day 7 until Day 30) CTC v. 3.0.

	Clo mg/m2. er Day × 5	Mel mg/m2	Enrolled	Hepatic		Renal			Sk	n		Other
Phase 1				Gr 1-2	Gr3-4	Gr 1-2	Gr 3-4	Gr 5	Gr 1-2	Gr 3-4	Gr 1-2	Gr 3-4	Gr 5
	10	100	1	1
	20	100	2		0						1 seizure
	30	100	2	2		3							1 cardiovascular
	40	100	1	1
	40	120	3	1	1	1				1
Phase 2	40	140	24	14(58%)	10(42%)	9 (37%)	4(17%)	1 (4%)	3(12%)	6 (25%)	1 confusion	1 a.fib,	1 cardiovascular
											1 a. flutter,	1 mucositis
											1 mucositis,	1 mental status changes
											1 pancreatitis
	30	140	27	16 (59%)	10(37%)	9 (33%)	7 (26%)		2 (7%)	1 (4%)	1 pancreatitis,	1 confusion, agitation	1 irreversible mental status changes
											1 mucositis,	2 severe mental status changes	1 pulmonary hemorrhage,
											1 seizure,		1 shock
											1 anxiety,
											1 pseudotumor cerebri
	30 (3h)	140	23	13 (56%)	9 (39%)	4(18%)	2(10%)	2(10%)	1 (4%)		1 mucositis,	1 pulmonary embolism	1 A fib with RVRand CHF
											1 diarrhea		1 anaphylactic reaction

Clo indicates clofarabine.